FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3096659726> ?p ?o ?g. }

• W3096659726 endingPage "22" @default.
• W3096659726 startingPage "21" @default.
• W3096659726 abstract "Kidney disease is a common complication that leads to increased morbidity and early mortality in patients with sickle cell disease (SCD). Vaso-occlusion, hyperfiltration, hypertension, and cell-free hemoglobin/heme-mediated toxicity may contribute to the pathophysiology of kidney disease. Treatments for SCD-related kidney disease have been adopted from therapies used to treat other SCD-related complications (hydroxyurea [HU]) or diabetic nephropathy (angiotensin converting enzyme [ACE]-inhibitors or angiotensin receptor blockers [ARBs]), although their effects on kidney function are not clear. We evaluated the effects of HU and ACE-inhibitors or ARBs on kidney function in a longitudinal cohort of 439 SCD patients enrolled into a prospective registry between 2011 and 2019. Patients were considered for the analysis if they had 6 months of kidney function values pre-therapy and remained on therapy for 6 months or longer. Changes in the estimated glomerular filtration rate (eGFR) and urine albumin concentration were compared prior to and after starting therapy using a mixed effects model. The effects of HU on kidney function were evaluated in 49 SCD patients. The mean age was 38 years (standard deviation [SD] 11 years), 43% were male, and 80% were Hb SS/Sβ0-thalassemia genotype. The eGFR improved from an average decline of -3.3 mL/min/1.73m2 in the 6 months prior to starting HU to an increase of +9.5 mL/min/1.73m2 during HU therapy (P = 0.0002) (Table). The average change in albuminuria also improved from an increase of +1.2 mg/g creatinine pre-HU therapy to a decline of -1.2 mg/g creatinine during HU therapy, although the difference was not statistically significant (P = 0.17). In 47 SCD patients started on ACE-inhibitors or ARBs, the mean age was 45 years (SD 11 years), 43% were male, and 87% were Hb SS/Sβ0-thalassemia genotype. During ACE-inhibitor or ARB therapy, there was no observed difference in the change in eGFR pre- versus during therapy (P = 0.9) (Table). Albuminuria improved from an average change of -1.0 mg/g creatinine pre-therapy to -1.6 mg/g creatinine during therapy (P = 0.009). Because clinical data are limited, current American Society of Hematology guidelines have conditional recommendations with low levels of certainty for the use of HU and ACE-inhibitors or ARBs to treat sickle cell nephropathy. In a longitudinal cohort of SCD patients, we demonstrate that during 6 months of therapy, there may be a benefit of HU in improving eGFR and of ACE-inhibitors or ARBs in reducing albuminuria. Larger and longer follow up studies of HU, ACE-inhibitors and ARBs as well as new targeted therapies to treat sickle cell nephropathy are urgently needed. Figure Disclosures Gordeuk: Novartis: Consultancy; Ironwood: Research Funding; CSL Behring: Consultancy, Research Funding; Global Blood Therapeutics: Consultancy, Research Funding; Imara: Research Funding. Saraf:Global Blood Therapeutics: Membership on an entity's Board of Directors or advisory committees, Other: Advisory Boards, Speakers Bureau; Novartis, Global Blood Therapeutics: Membership on an entity's Board of Directors or advisory committees; Pfizer, Global Blood Therapeutics, Novartis: Research Funding." @default.
• W3096659726 created "2020-11-09" @default.
• W3096659726 creator A5010079454 @default.
• W3096659726 creator A5012936630 @default.
• W3096659726 creator A5029326604 @default.
• W3096659726 creator A5030174386 @default.
• W3096659726 creator A5048176086 @default.
• W3096659726 creator A5061639314 @default.
• W3096659726 creator A5068456972 @default.
• W3096659726 creator A5091014069 @default.
• W3096659726 date "2020-11-05" @default.
• W3096659726 modified "2023-09-27" @default.
• W3096659726 title "Effects of Hydroxyurea and Renin-Angiotensin Blockade on Kidney Function in Sickle Cell Disease" @default.
• W3096659726 doi "https://doi.org/10.1182/blood-2020-138753" @default.
• W3096659726 hasPublicationYear "2020" @default.
• W3096659726 type Work @default.
• W3096659726 sameAs 3096659726 @default.
• W3096659726 citedByCount "0" @default.
• W3096659726 crossrefType "journal-article" @default.
• W3096659726 hasAuthorship W3096659726A5010079454 @default.
• W3096659726 hasAuthorship W3096659726A5012936630 @default.
• W3096659726 hasAuthorship W3096659726A5029326604 @default.
• W3096659726 hasAuthorship W3096659726A5030174386 @default.
• W3096659726 hasAuthorship W3096659726A5048176086 @default.
• W3096659726 hasAuthorship W3096659726A5061639314 @default.
• W3096659726 hasAuthorship W3096659726A5068456972 @default.
• W3096659726 hasAuthorship W3096659726A5091014069 @default.
• W3096659726 hasBestOaLocation W30966597261 @default.
• W3096659726 hasConcept C126322002 @default.
• W3096659726 hasConcept C126894567 @default.
• W3096659726 hasConcept C134018914 @default.
• W3096659726 hasConcept C159641895 @default.
• W3096659726 hasConcept C2776174234 @default.
• W3096659726 hasConcept C2778653478 @default.
• W3096659726 hasConcept C2780091579 @default.
• W3096659726 hasConcept C2780306776 @default.
• W3096659726 hasConcept C2781184683 @default.
• W3096659726 hasConcept C555293320 @default.
• W3096659726 hasConcept C71924100 @default.
• W3096659726 hasConcept C90924648 @default.
• W3096659726 hasConceptScore W3096659726C126322002 @default.
• W3096659726 hasConceptScore W3096659726C126894567 @default.
• W3096659726 hasConceptScore W3096659726C134018914 @default.
• W3096659726 hasConceptScore W3096659726C159641895 @default.
• W3096659726 hasConceptScore W3096659726C2776174234 @default.
• W3096659726 hasConceptScore W3096659726C2778653478 @default.
• W3096659726 hasConceptScore W3096659726C2780091579 @default.
• W3096659726 hasConceptScore W3096659726C2780306776 @default.
• W3096659726 hasConceptScore W3096659726C2781184683 @default.
• W3096659726 hasConceptScore W3096659726C555293320 @default.
• W3096659726 hasConceptScore W3096659726C71924100 @default.
• W3096659726 hasConceptScore W3096659726C90924648 @default.
• W3096659726 hasIssue "Supplement 1" @default.
• W3096659726 hasLocation W30966597261 @default.
• W3096659726 hasOpenAccess W3096659726 @default.
• W3096659726 hasPrimaryLocation W30966597261 @default.
• W3096659726 hasRelatedWork W2113389249 @default.
• W3096659726 hasRelatedWork W2124543160 @default.
• W3096659726 hasRelatedWork W2494555525 @default.
• W3096659726 hasRelatedWork W2616483297 @default.
• W3096659726 hasRelatedWork W2742107035 @default.
• W3096659726 hasRelatedWork W2949007128 @default.
• W3096659726 hasRelatedWork W3011886700 @default.
• W3096659726 hasRelatedWork W3132812123 @default.
• W3096659726 hasRelatedWork W4243973908 @default.
• W3096659726 hasRelatedWork W656697013 @default.
• W3096659726 hasVolume "136" @default.
• W3096659726 isParatext "false" @default.
• W3096659726 isRetracted "false" @default.
• W3096659726 magId "3096659726" @default.
• W3096659726 workType "article" @default.